Mereo BioPharma Group PLC ADR (MREO) — Cash Flow-to-Debt Ratio
Mereo BioPharma Group PLC ADR (MREO) has a Cash Flow-to-Debt Ratio of -1.00x as of June 2026, meaning its operating cash flow of $-6.04 Million could theoretically repay -1% of its total liabilities ($6.06 Million) in one year. See how financially flexible is Mereo BioPharma Group PLC ADR to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Mereo BioPharma Group PLC ADR Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Mereo BioPharma Group PLC ADR across 11 annual periods. For the full cash flow conversion analysis, see how efficiently does Mereo BioPharma Group PLC ADR generate cash.
Annual Cash Flow-to-Debt Ratio for Mereo BioPharma Group PLC ADR (2015–2025)
Year-by-year debt coverage analysis for Mereo BioPharma Group PLC ADR. Check MREO cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.19x | $-30.97 Million | $5.00 Million | ▼ -190.9% |
| 2024 | -2.13x | $-32.83 Million | $15.42 Million | ▼ -60.8% |
| 2023 | -1.32x | $-21.13 Million | $15.96 Million | ▲ +29.5% |
| 2022 | -1.88x | $-48.82 Million | $26.01 Million | ▼ -1279.0% |
| 2021 | -0.14x | $-7.07 Million | $51.95 Million | ▲ +62.5% |
| 2020 | -0.36x | $-38.62 Million | $106.55 Million | ▲ +63.2% |
| 2019 | -0.98x | $-60.22 Million | $61.19 Million | ▼ -46.8% |
| 2018 | -0.67x | $-23.14 Million | $34.51 Million | ▲ +29.4% |
| 2017 | -0.95x | $-32.15 Million | $33.85 Million | ▲ +74.0% |
| 2016 | -3.65x | $-27.40 Million | $7.51 Million | ▼ -213.6% |
| 2015 | -1.16x | $-6.70 Million | $5.76 Million | — |